证券代码：688212 证券简称：澳华内镜 公告编号：2023-039 上海澳华内镜股份有限公司 关于公司会计估计变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》 的规定，本次固定资产折旧年限的调整属于会计估计变更，应当采用未来适用法 进行处理，无需进行追溯调整，不会对上海澳华内镜股份有限公司（以下简称"公 司"）以往年度的财务状况和经营成果产生影响。 二、具体情况及对公司的影响 （一）会计估计变更的具体情况 本次会计估计变更自 2023 年 1 月 1 日起执行，以 2022 年 12 月 31 日 的固定资产为基础，假设不考虑 2022 年 12 月 31 日之后固定资产的增减变动， 根据变更后的固定资产折旧年限测算，预计 2023 年度折旧额减少 124.71 万元， 净利润增加约 124.71 万元，该部分资产折旧年限变更对以后年度财务状况及经 营成果不会产生重大影响。 一、本次会计估计变更概述 为了更加公允、适当地反映公司 ...

上海澳华内镜股份有限公司 章程 二〇二三年八月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | | 股份增减和回购 5 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东大会 | 7 | | 第一节 | 股东 | 7 | | 第二节 | | 股东大会的一般规定 9 | | 第三节 | | 股东大会的召集 13 | | 第四节 | | 股东大会的提案与通知 15 | | 第五节 | | 股东大会的召开 16 | | 第六节 | | 股东大会的表决和决议 19 | | 第五章 | 董事会 | 23 | | 第一节 | 董事 | 23 | | 第二节 | 董事会 | 26 | | 第三节 | | 董事会专门委员会 32 | | 第四节 | | 董事会秘书 33 | | 第六章 | | 总经理及其他高级管理人员 34 | | 第七章 | 监事会 | 36 | | 第一节 | 监事 | 36 | | 第二节 | 监事会 | 37 | | 第八章 ...

一、本次计提减值准备情况概述 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、准确地 反映公司截至 2023 年 6 月 30 日的财务状况，本着谨慎性原则，公司对截至 2023 年 6 月 30 日公司及下属子公司的资产进行了减值测试，对可能发生资产减值损失的相关资产计 提减值准备。2023 年半年度计提的资产减值准备为 775.15 万元。具体情况如下表所示： 单位：万元 | 项目 | 2023 年半年度计提金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 359.13 | 含应收账款坏账损失及其他应收款坏账损失 | | 资产减值损失 | 416.02 | 存货跌价损失及合同履约成本减值损失 | | 合计 | 775.15 | —— | 二、计提资产减值准备事项的具体说明 证券代码：688212 证券简称：澳华内镜 公告编号：2023-040 上海澳华内镜股份有限公司 关于2023年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海澳华 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2023-041 上海澳华内镜股份有限公司 关于变更注册资本暨修订《公司章程》的公告 公司 2022 年限制性股票激励计划首次授予部分第一个归属期归属事项已于 2023 年 6 月 5 日完成股份登记工作，归属股票数量 61.50 万股，并于 2023 年 6 月 9 日上市流通。本次限制性股票归属后，公司股本总数由 133,340,000 股增加 至 133,955,000 股 ， 注 册 资 本 由 人 民 币 133,340,000 元 增 加 至 人 民 币 133,955,000 元。 二、修订公司章程的情况 根据上述变更事项，公司拟对《公司章程》进行修订，具体修订内容如下： | | 修订前 | | 修订后 | | | | --- | --- | --- | --- | --- | --- | | 第六条 | 公司注册资本：人民币 | 13,334.00 | 第六条 | 公司注册资本：人民币 | 133,955,000 | | 万元。 | | | 元。 | | | | 第十九条 | 公司股份总数为 13,334 | 万股，均 | 第十九条 | 公 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2023-038 上海澳华内镜股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 08 月 16 日（星期三）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 09 日（星期三）至 08 月 15 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aohua.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海澳华内镜股份有限公司（以下简称"公司"）将于 2023 年 08 月 15 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况，公司计划 ...

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板 公司具有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长 期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场 风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 青岛盘古智能制造股份有限公司 （山东省青岛市高新区科海路 77 号） 首次公开发行股票并在创业板上市 招股意向书 （成都市青羊区东城根上街 95 号） 保荐人（主承销商） 青岛盘古智能制造股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注 册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对 发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资 风险。 发行人及全体董事、监事、高级管理人员承诺招股意向书 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2023-017 上海澳华内镜股份有限公司 关于参加 2022 年度医疗器械专场集体业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 4 月 28 日（星期五）9:00-11:00 会议召开方式：视频和线上文字互动 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 4 月 27 日（星期四）16:00 前通过邮件、电话、传 真等形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投 资者普遍关注的问题进行回答。 上海澳华内镜股份有限公司 （以下简称"公司"）将于 2023 年 4 月 25 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2022 年度医 疗器械专场 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥113,420,020.99, representing a year-on-year increase of 37.96%[8] - The net profit attributable to shareholders for Q3 2022 was ¥3,514,697.77, a decrease of 69.66% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥2,808,628.35, down 75.32% year-on-year[8] - Total revenue for the first three quarters of 2022 reached ¥280,772,884.24, an increase of 22.6% compared to ¥229,113,972.10 in the same period of 2021[32] - Net profit for the first three quarters of 2022 was ¥10,263,456.13, a decrease of 54.5% from ¥22,539,049.94 in the same period of 2021[35] - The total comprehensive income for the first three quarters of 2022 was ¥8,741,000.41, down from ¥21,120,198.68 in the same period of 2021[37] - The total profit for the first three quarters of 2022 was a loss of ¥11,911,163.87, contrasting with a profit of ¥10,118,048.69 in the same period of 2021[51] Research and Development - The total R&D investment for Q3 2022 was ¥22,579,770.30, an increase of 90.23% compared to the same period last year[12] - R&D investment accounted for 19.91% of operating revenue in Q3 2022, an increase of 5.47 percentage points year-on-year[12] - Research and development expenses increased to ¥59,496,193.03 in 2022, up 68.7% from ¥35,236,256.75 in 2021[35] - Research and development expenses increased significantly to ¥59,721,194.66, up 71.2% from ¥34,885,391.56 in the previous year[50] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥63,895,060.94, a decrease of 310.42% compared to the same period last year[12] - Cash flow from operating activities for the first three quarters of 2022 was ¥260,492,218.38, compared to ¥243,100,349.50 in 2021, indicating a 7.1% increase[37] - The net cash flow from investment activities was CNY -205,746,180.24 for the first three quarters of 2022, compared to CNY -64,968,651.18 in the same period of 2021, indicating a worsening investment cash flow situation[40] - The company's cash and cash equivalents decreased to ¥466,394,364.86 from ¥766,817,412.06, representing a decline of about 39.2% year-over-year[27] - The company's total current assets decreased slightly to ¥980,439,819.97 from ¥996,905,219.79, a decline of approximately 1.6%[27] - The company's cash inflow from investment activities was CNY 590,373,712.87 in 2022, a substantial increase from CNY 105,163,388.58 in 2021, representing an increase of approximately 461.0%[40] - The company reported a net increase in cash and cash equivalents of CNY -300,423,047.20 for the first three quarters of 2022, compared to CNY -41,866,961.28 in the same period of 2021, indicating a worsening cash position[42] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥1,381,637,306.61, an increase of 2.40% from the end of the previous year[12] - The company's total liabilities as of September 30, 2022, were ¥82,932,006.01, compared to ¥58,982,132.82 at the end of 2021, reflecting an increase of approximately 40.5%[30] - Non-current assets totaled ¥401,197,486.64, up from ¥352,330,037.69, which is an increase of about 13.9% year-over-year[30] - The total liabilities as of September 30, 2022, amounted to ¥126,560,495.05, compared to ¥90,356,468.99 at the end of 2021, reflecting a 40.0% increase[32] - The company's total equity decreased to CNY 1,202,889,957.60 as of September 30, 2022, down from CNY 1,218,639,646.70 at the end of December 2021, indicating a decline of about 1.3%[48] Earnings Per Share - Basic earnings per share for Q3 2022 were ¥0.02, down 81.67% year-on-year[12] - The company reported a basic earnings per share of ¥0.06 for the first three quarters of 2022, down from ¥0.21 in the same period of 2021[37] Future Outlook - The company plans to continue enhancing product upgrades and market promotion to drive future growth[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[30]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million CNY for the first half of 2022, representing a 20% growth compared to the same period last year[18]. - The company's operating revenue for the first half of 2022 was CNY 167,352,863.25, representing a year-on-year increase of 13.92%[26]. - The net profit attributable to shareholders for the same period was CNY 5,067,376.68, a decrease of 44.71% compared to the previous year[26]. - The net profit after deducting non-recurring gains and losses was CNY 1,561,681.76, down 80.40% year-on-year[28]. - The net cash flow from operating activities was negative CNY 35,832,709.47, a decline of 238.94% compared to the previous year[28]. - The company's total assets at the end of the reporting period were CNY 1,362,574,920.04, an increase of 0.99% from the end of the previous year[28]. - The net assets attributable to shareholders decreased by 1.09% to CNY 1,235,029,764.68 compared to the end of the previous year[28]. - The basic earnings per share for the first half of 2022 were CNY 0.04, a decrease of 55.56% year-on-year[28]. - The company recognized government subsidies amounting to CNY 816,954.79 during the reporting period[32]. - The total non-recurring gains and losses amounted to CNY 3,505,694.92, after tax effects[34]. Market Outlook and Strategy - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% based on new product launches and market expansion strategies[18]. - The company is planning to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[18]. - The company has successfully completed a strategic acquisition of a local competitor, which is anticipated to contribute an additional 100 million CNY in annual revenue[18]. - The company has outlined a new strategy focusing on digital transformation, aiming to increase online sales by 40% in the next fiscal year[18]. Research and Development - The company has invested 50 million CNY in R&D for new technologies aimed at improving product efficiency and user experience[18]. - The R&D investment accounted for 22.06% of operating revenue, an increase of 6.15 percentage points compared to the previous year[28]. - The company achieved a total R&D investment of ¥36,916,422.73, representing a 57.99% increase compared to ¥23,366,316.02 in the previous year[60]. - The company employed 163 R&D personnel, which is 22.89% of the total workforce, up from 20.81% in the previous year[70]. - The company has developed key technologies in optical imaging, image processing, and electrical control, establishing a strong competitive advantage in the flexible endoscope market[42]. - The company has established four R&D centers across the country, enhancing its innovation capabilities in optical imaging and image processing[71]. - The company has added 14 new patents during the reporting period, including 11 invention patents, 2 utility model patents, and 1 design patent, enhancing its competitive edge in the endoscope field[56]. - The company has a cumulative total of 110 invention patent applications, with 37 patents granted, indicating a strong focus on innovation[56]. Product Development - New product development includes the introduction of the AQ-300 system, which is expected to enhance the company's competitive edge in the medical imaging market[18]. - The company has launched multiple new products, including a 4K ultra-high-definition flexible endoscope system and an animal endoscope system[66]. - In May 2022, the company introduced the AQL-200L, a new generation intelligent multi-spectral endoscope, featuring LED light sources and multiple imaging modes to better meet clinical needs[81]. - The company has made significant progress in the development of the AQ-200 system upgrade, with a total investment of ¥28,000,000 and ongoing R&D for multiple devices[64]. Market and Competitive Landscape - The global medical device market size exceeded $440 billion in 2020 and is expected to surpass $800 billion by 2030, with a CAGR of 6.3% from 2020 to 2030[37]. - China's medical device market grew from ¥312.55 billion in 2015 to ¥778.93 billion in 2020, with a CAGR of approximately 20.0%, and is projected to exceed ¥2200 billion by 2030, with a CAGR of 11.2% from 2020 to 2030[37]. - The domestic medical endoscope market size was ¥23.1 billion in 2020 and is expected to grow to ¥62.4 billion by 2030, with a CAGR of 10.5%[38]. - The company faces a market share risk, holding less than 5% of the domestic market compared to competitors with over 90% market share[92]. Financial Management and Risks - The company has maintained a strong balance sheet with a cash reserve of 200 million CNY, providing flexibility for future investments and acquisitions[18]. - The company's accounts receivable at the end of the reporting period amounted to 95.37 million yuan, representing 7.00% of total assets, indicating an increase in receivables risk[99]. - The company is at risk of supply chain disruptions for imported raw materials, which are primarily sourced from U.S. and Japanese suppliers[93]. - The company faces risks related to changes in industry policies that could adversely affect its main business operations[102]. Corporate Governance and Compliance - The company has reported no significant non-operational fund occupation by controlling shareholders, ensuring financial integrity[18]. - The company has not engaged in any illegal activities or received penalties during the reporting period[171]. - The company has established compliance measures for shareholding changes in accordance with relevant laws and regulations[141]. - There were no significant lawsuits or arbitration matters during the reporting period[171]. Shareholder Engagement and Incentives - The company granted 2.24 million restricted stock units to 66 eligible employees as part of its employee equity incentive plan, aligning employee interests with company performance[86]. - The company has approved a restricted stock incentive plan, granting 2.24 million shares at a price of CNY 22.50 per share to 66 eligible employees[126]. - The company will ensure that any related transactions comply with relevant laws and regulations[165]. Investment and Fund Utilization - The total amount of raised funds was RMB 750,150,000, with a net amount of RMB 659,178,031.66 after deducting issuance costs[180]. - The total committed investment amount for raised funds was RMB 640,000,000, with a cumulative investment of RMB 167,431,282.70 by the end of the reporting period, representing 26.16% of the planned investment[180]. - The supplementary working capital project has a committed investment of RMB 120,000,000, with a cumulative investment of RMB 120,000,000, achieving 100% of the planned investment[184].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：688212 证券简称：澳华内镜 上海澳华内镜股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|------------------------------------------| | 项目 | 本报告期 | 本报告期比上年 \n同期增减变动幅 \n度 (%) | | 营业收入 | 81,608, ...